Overview
Financials
Revenue history (in m)
Financial insight
- The statement flags a going concern risk. Na dzień 31 grudnia 2025 r. skumulowane straty wyniosły 52.007.139,64 zł i przewyższyły sumę kapitału zapasowego i kapitałów rezerwowych oraz połowę kapitału zakładowego o kwotę 52.004.639,64 zł. Stosownie do wymogów art. 233 ustawy z dnia 7.12.2023 r. KSH (Dz.U. z 2024 r. poz. 18) Nadzwyczajne Zgromadzenie Wspólników w dniu 06.03.2026 r. podjęło uchwałę o kontynuowaniu działalności firmy. Spółka posiada zapewniony dostęp do finansowania w ramach grupowego systemu cash pool oraz w razie potrzeby, możliwość pozyskania środków w formie pożyczek wewnątrzgrupowych. W dniu 15.06.2026. otrzymała, pośrednio poprzez swojego udziałowca Spółkę DR.MAX Sp. z o.o., list wsparcia, w którym właściciel, Pharmax Holdings Limited, potwierdza wolę wsparcia finansowego Spółki.
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
3 of 4 financial statements were filed late (the longest delay 44 days for 2022). 1 of 4 audited by a statutory auditor.
- 202506/07/2026
- 202417/07/2025
- 202324/07/2024
- 202228/08/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Authorized Representatives
Manner of representation
If the management board is a multi-member management board, joint action of two members of the management board, or one member of the management board together with a commercial proxy, is required to make declarations on behalf of the company. If the management board is a one-person management board, the President of the Management Board represents the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 100,000 | $1,350,621.29 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2022-01-01.
41 1050 0086 1000 0090 3287 1684
85 1050 0086 1000 0090 3287 1668
19 1050 0086 1000 0090 3287 1692
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 3MPLN 2,954,727 |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Pfizer Trading Polska sp. z o.o. | $299,067,553.99 | pfizer.pl | ||
| Asclepios S.A. | $291,166,555.86 | asclepios.pl | ||
| Medi&More sp. z o.o. | $275,638,188.29 | medi-more.pl | ||
| Novo S.A. | $209,522,261.96 | novo-sa.pl | ||
| Bialmed sp. z o.o. | $203,238,055.12 | bialmed.pl | ||
| Medivet S.A. | $168,623,782.61 | medivet.pl | ||
| Servier Polska Services sp. z o.o. | $157,143,144.15 | servier.pl | ||
| Przedsiębiorstwo Zaopatrzenia Aptek Multi Pharme S.A. | $146,864,520.79 | multipharme.pl | ||
| Lubfarm S.A. | $123,208,945.21 | lubfarm.pl | ||
| Nettle S.A. | $85,124,937.06 | nettle.pl |
Change history
FAQ
Last updated: 2026-10-09